Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report)’s share price traded up 6.7% on Friday after Wells Fargo & Company raised their price target on the stock from $79.00 to $112.00. Wells Fargo & ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report) today and set a price target of ...

(RTTNews) - Tectonic Therapeutic Inc. (TECX), a clinical-stage biotechnology company, on Thursday announced positive interim data from its ongoing Phase 1b clinical trial of TX45 in patients with ...

Tectonic Therapeutic (TECX) announced that it has entered into a securities purchase agreement for a private investment in public equity ...

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a ...

Tectonic Therapeutic (NASDAQ:TECX) has announced a ~$185M capital raise to fund the clinical development of its drug candidates. Pursuant to the terms of the securities purchase agreement, at the ...

Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...